Arrowhead Pharma (ARWR): רווח נקי למניה ב-12 החודשים האחרונים

Arrowhead Pharmaceuticals (ARWR) success is based on the test results of therapies for liver and cardiovascular pathologies. The annual net income per share trend visualizes these expectations, where the -5.09 indicator determines the magnitude of the metric. Growth relies on the TRiM platform with a high barrier to entry, while financial stability is supported by licensing royalties from the world's largest pharmaceutical behemoths.

This indicator measures the total return of a single stock over a rolling year, allowing for an assessment of the business's actual ability to generate profit after all expenses. By analyzing annual net income per share, an investor can see the impact of the costly cold chain logistics for RNA drugs on the margins of Arrowhead Pharmaceuticals (ARWR), which is critical for understanding the company's financial stability.